Compare EQBK & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | BLFS |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.8M | 923.5M |
| IPO Year | 2015 | 2013 |
| Metric | EQBK | BLFS |
|---|---|---|
| Price | $43.77 | $19.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $50.50 | $32.00 |
| AVG Volume (30 Days) | 96.3K | ★ 499.9K |
| Earning Date | 04-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ 77.27 |
| EPS | ★ 1.23 | N/A |
| Revenue | N/A | ★ $96,214,000.00 |
| Revenue This Year | $74.58 | $19.73 |
| Revenue Next Year | $5.11 | $17.82 |
| P/E Ratio | $35.76 | ★ N/A |
| Revenue Growth | N/A | ★ 16.97 |
| 52 Week Low | $34.11 | $17.86 |
| 52 Week High | $50.07 | $29.57 |
| Indicator | EQBK | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 45.75 |
| Support Level | $42.84 | $17.86 |
| Resistance Level | $44.50 | $26.77 |
| Average True Range (ATR) | 1.11 | 0.82 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 35.95 | 76.63 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.